KemPharm Inc (NASDAQ:KMPH) has been assigned a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $10.50.

Several equities analysts have weighed in on the company. ValuEngine lowered KemPharm from a “buy” rating to a “hold” rating in a research note on Tuesday, September 4th. Oppenheimer set a $11.00 target price on KemPharm and gave the company a “buy” rating in a research note on Thursday. Canaccord Genuity reissued a “buy” rating and issued a $11.00 target price on shares of KemPharm in a research note on Tuesday, August 14th. Zacks Investment Research lowered KemPharm from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. Finally, CIBC reissued an “outperform” rating on shares of KemPharm in a research note on Friday, September 21st.

Shares of KMPH traded up $0.05 during trading hours on Friday, hitting $2.35. 158,091 shares of the stock traded hands, compared to its average volume of 583,369. KemPharm has a 1-year low of $2.00 and a 1-year high of $8.40.

KemPharm (NASDAQ:KMPH) last released its earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.31. Research analysts anticipate that KemPharm will post -3.11 EPS for the current fiscal year.

In related news, major shareholder Delaware Street Capital Master bought 304,283 shares of the business’s stock in a transaction on Monday, July 30th. The shares were purchased at an average price of $4.00 per share, with a total value of $1,217,132.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 2,316,933 shares of company stock worth $7,249,593 in the last three months. Insiders own 25.90% of the company’s stock.

Several institutional investors have recently made changes to their positions in KMPH. Cowen Inc. acquired a new position in KemPharm during the second quarter worth about $2,381,000. Millennium Management LLC grew its holdings in KemPharm by 878.0% during the second quarter. Millennium Management LLC now owns 151,250 shares of the specialty pharmaceutical company’s stock worth $983,000 after acquiring an additional 135,784 shares during the period. Renaissance Technologies LLC grew its holdings in KemPharm by 101.1% during the second quarter. Renaissance Technologies LLC now owns 181,800 shares of the specialty pharmaceutical company’s stock worth $1,182,000 after acquiring an additional 91,400 shares during the period. Spark Investment Management LLC acquired a new position in KemPharm during the second quarter worth about $176,000. Finally, C WorldWide Group Holding A S grew its holdings in KemPharm by 3.2% during the second quarter. C WorldWide Group Holding A S now owns 399,999 shares of the specialty pharmaceutical company’s stock worth $2,600,000 after acquiring an additional 12,319 shares during the period. Institutional investors own 39.22% of the company’s stock.

KemPharm Company Profile

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

Recommended Story: Diversification

Analyst Recommendations for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.